- Home
- ABBV
ABBV
AbbVie Inc.
as 06-28-2024 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 277.3B | IPO Year: | N/A |
| Target Price: | $185.00 | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | 3.62% | Dividend Payout Frequency: | Quarterly |
| EPS: | 3.37 | EPS Growth: | -20.52 |
| 52 Week Low/High: | $132.70 - $182.89 | Next Earning Date: | 07-25-2024 |
| Revenue: | $54,403,000,000 | Revenue Growth: | -4.12% |
| Revenue Growth (this year): | 3.67% | Revenue Growth (next year): | 5.69% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | ABBV | EVP, CHIEF BUS/STRAT OFFICER | Mar 20 '24 | Sell | $176.30 | 21,082 | $3,716,756.60 | 55,903 | SEC Form 4 |
| Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 18 '24 | Sell | $178.85 | 26,110 | $4,669,773.50 | 93,780 | SEC Form 4 |
| Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 18 '24 | Sell | $179.03 | 5,099 | $912,873.97 | 88,681 | SEC Form 4 |
| Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 18 '24 | Sell | $178.69 | 27,740 | $4,956,860.60 | 60,941 | SEC Form 4 |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $176.40 | 15,412 | $2,718,676.80 | 74,105 | SEC Form 4 |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $177.71 | 30,288 | $5,382,480.48 | 43,817 | SEC Form 4 |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $176.35 | 9,853 | $1,737,576.55 | 33,964 | SEC Form 4 |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Mar 1 '24 | Sell | $177.71 | 20,127 | $3,576,769.17 | 13,837 | SEC Form 4 |
| Michael Robert A. | ABBV | PRES & CHIEF OPERATING OFFICER | Feb 28 '24 | Sell | $176.44 | 21,560 | $3,804,046.40 | 145,964 | SEC Form 4 |
| Michael Robert A. | ABBV | PRES & CHIEF OPERATING OFFICER | Feb 28 '24 | Sell | $176.46 | 47,319 | $8,349,910.74 | 98,645 | SEC Form 4 |
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 28 '24 | Sell | $177.05 | 6,504 | $1,151,533.20 | 13,784 | SEC Form 4 |
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 28 '24 | Sell | $178.04 | 3,387 | $603,021.48 | 10,397 | SEC Form 4 |
| GONZALEZ RICHARD A | ABBV | CHAIRMAN OF THE BOARD AND CEO | Feb 28 '24 | Sell | $177.27 | 138,616 | $24,572,458.32 | 519,099 | SEC Form 4 |
| Buckbee Kevin K | ABBV | SVP, CONTROLLER | Feb 28 '24 | Sell | $176.65 | 5,144 | $908,687.60 | 6,983 | SEC Form 4 |
| Reents Scott T | ABBV | EVP, CHIEF FINANCIAL OFFICER | Feb 23 '24 | Sell | $177.44 | 14,140 | $2,509,001.60 | 27,065 | SEC Form 4 |
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 23 '24 | Sell | $177.51 | 13,753 | $2,441,295.03 | 28,173 | SEC Form 4 |
| SALEKI-GERHARDT AZITA | ABBV | EVP, CHIEF OPERATIONS OFFICER | Feb 21 '24 | Sell | $173.71 | 52,870 | $9,184,047.70 | 243,944 | SEC Form 4 |
| Donoghoe Nicholas | ABBV | EVP, CHIEF BUS/STRAT OFFICER | Dec 26 '23 | Sell | $154.72 | 2,912 | $450,544.64 | 55,903 | SEC Form 4 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
2 days ago
How Medicare drug price negotiations could hit pharma stocks
Pharmaceutical Technology
2 days ago
Coherus offloads Humira biosimilar Yusimry for $40m
Simply Wall St.
2 days ago
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
Zacks
2 days ago
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
Zacks
2 days ago
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
Zacks
2 days ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Pharmaceutical Technology
2 days ago
AbbVie completes acquisition of Celsius Therapeutics for $250m
MT Newswires
2 days ago
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.